CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
연구 개요
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving CC-99282 with rituximab may be a safe and effective treatment option for patients who have received CAR-T cell therapy for relapsed or refractory non-Hodgkin's lymphoma.
- 스폰서
- 협력: BMS
- 적응증
- B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
- 중재
- Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography, Rituximab
- 목표 등록
- 18명
- 시작일
- 2024-01-29
- 완료(예정)
- 2026-12-31
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.